Cargando...
Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer
The PI3K/AKT pathway is frequently altered in advanced human prostate cancer mainly through the loss of functional PTEN, and presents as potential target for personalized therapy. Our aim was to determine the therapeutic potential of the pan-AKT inhibitor, AZD5363, in PTEN-deficient prostate cancer....
Guardado en:
| Publicado en: | Oncotarget |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Impact Journals LLC
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4941290/ https://ncbi.nlm.nih.gov/pubmed/26910118 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7557 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|